AbbVie Reconciled Depreciation from 2010 to 2024

ABBV Stock  USD 175.67  0.90  0.51%   
AbbVie Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation will likely drop to about 5.9 B in 2024. During the period from 2010 to 2024, AbbVie Reconciled Depreciation regression line of quarterly data had mean square error of 3453198 T and geometric mean of  2,646,767,768. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2011-03-31
Previous Quarter
2.1 B
Current Value
2.1 B
Quarterly Volatility
852.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 B, Interest Expense of 1.1 B or Selling General Administrative of 7.8 B, as well as many indicators such as Price To Sales Ratio of 3.39, Dividend Yield of 0.0289 or PTB Ratio of 17.2. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of AbbVie Inc over the last few years. It is AbbVie's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

AbbVie Reconciled Depreciation Regression Statistics

Arithmetic Mean3,588,695,238
Geometric Mean2,646,767,768
Coefficient Of Variation84.41
Mean Deviation2,679,593,651
Median1,501,000,000
Standard Deviation3,029,236,421
Sample Variance9176273.3T
Range7.2B
R-Value0.81
Mean Square Error3453198T
R-Squared0.65
Significance0.0003
Slope546,339,286
Total Sum of Squares128467826.1T

AbbVie Reconciled Depreciation History

20245.9 B
20238.7 B
20228.5 B
20218.5 B
20206.5 B
2019B
20181.8 B

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation8.7 B5.9 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.